The 1st Patient-Centric Autologous Supply Chain deliver supply chain and logistics managers, hospitals and operations stakeholders from both large and small pharma provide practical knowledge to optimize and re-design your processes, while ensuring that you have the right technologies and partners to ensure a patient-centric supply chain in the commercial world.
The theme of the Forum focuses on Integrating Process and Technology to Patient-Centric Autologous Supply Chain.
Patient-Centric Autologous Supply Chain will provide knowledge and solutions to address seriously redesign and standardize processes, incorporate real time visibility technology and for the first time, take full responsibility for the entire supply chain (hence fully patient-centric).
The pharma industry stands at a defining moment.
Unlike many other immuno-oncology drugs, CAR-T therapies present unique supply chain challenges. Their production begins with the extraction of T cells from a cancer patient. The cells are shipped to a manufacturing facility, where they're genetically engineered to more effectively target tumors before being sent back for infusion.
CAR-T therapies evolved from a novel idea to a realized market. New software platforms now provide drug companies with more comprehensive data on who handled the therapy last or what stage it's at within the supply chain. And advancements in cold storage, containers and technology integration have made shipping the therapies more viable.
Given the potential health risks, personalized therapies also require a full-proof chain of identity that makes clear the specific patient who is to receive the therapy.
While every stage has its providers, where is no clear understanding of how to go from A to B and back.